BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22684020)

  • 21. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer.
    Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
    Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycosylation of KEAP1 links nutrient sensing to redox stress signaling.
    Chen PH; Smith TJ; Wu J; Siesser PF; Bisnett BJ; Khan F; Hogue M; Soderblom E; Tang F; Marks JR; Major MB; Swarts BM; Boyce M; Chi JT
    EMBO J; 2017 Aug; 36(15):2233-2250. PubMed ID: 28663241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AURKA emerges as a vulnerable target for KEAP1-deficient non-small cell lung cancer by activation of asparagine synthesis.
    Deng B; Liu F; Chen N; Li X; Lei J; Chen N; Wu J; Wang X; Lu J; Fang M; Chen A; Zhang Z; He B; Yan M; Zhang Y; Wang Z; Liu Q
    Cell Death Dis; 2024 Mar; 15(3):233. PubMed ID: 38521813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPIA dictates NRF2 stability to promote lung cancer progression.
    Lu W; Cui J; Wang W; Hu Q; Xue Y; Liu X; Gong T; Lu Y; Ma H; Yang X; Feng B; Wang Q; Zhang N; Xu Y; Liu M; Nussinov R; Cheng F; Ji H; Huang J
    Nat Commun; 2024 Jun; 15(1):4703. PubMed ID: 38830868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An antioxidant feedforward cycle coordinated by linker histone variant H1.2 and NRF2 that drives nonsmall cell lung cancer progression.
    Chen Y; Shi J; Wang X; Zhou L; Wang Q; Xie Y; Peng C; Kuang L; Yang D; Yang J; Yang C; Li X; Yuan Y; Zhou Y; Peng A; Zhang Y; Chen H; Liu X; Zheng L; Huang K; Li Y
    Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2306288120. PubMed ID: 37729198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.
    Cardnell RJ; Behrens C; Diao L; Fan Y; Tang X; Tong P; Minna JD; Mills GB; Heymach JV; Wistuba II; Wang J; Byers LA
    Clin Cancer Res; 2015 Aug; 21(15):3480-91. PubMed ID: 25878335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nrf2: friend or foe for chemoprevention?
    Kensler TW; Wakabayashi N
    Carcinogenesis; 2010 Jan; 31(1):90-9. PubMed ID: 19793802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
    Pillai R; LeBoeuf SE; Hao Y; New C; Blum JLE; Rashidfarrokhi A; Huang SM; Bahamon C; Wu WL; Karadal-Ferrena B; Herrera A; Ivanova E; Cross M; Bossowski JP; Ding H; Hayashi M; Rajalingam S; Karakousi T; Sayin VI; Khanna KM; Wong KK; Wild R; Tsirigos A; Poirier JT; Rudin CM; Davidson SM; Koralov SB; Papagiannakopoulos T
    Sci Adv; 2024 Mar; 10(13):eadm9859. PubMed ID: 38536921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
    Bottoni L; Minetti A; Realini G; Pio E; Giustarini D; Rossi R; Rocchio C; Franci L; Salvini L; Catona O; D'Aurizio R; Rasa M; Giurisato E; Neri F; Orlandini M; Chiariello M; Galvagni F
    Oncogene; 2024 May; 43(22):1701-1713. PubMed ID: 38600165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaping Induced Cannabidiol (CBD) Oxidation Product CBD Quinone Forms Protein Adducts with KEAP1 and Activates KEAP1-Nrf2 Genes.
    Love CA; Kim HH; Tallman KA; Clapp PW; Porter NA; Jaspers I
    Chem Res Toxicol; 2023 Apr; 36(4):565-569. PubMed ID: 36999736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NRF2 and the Hallmarks of Cancer.
    Rojo de la Vega M; Chapman E; Zhang DD
    Cancer Cell; 2018 Jul; 34(1):21-43. PubMed ID: 29731393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NRF2 Serves a Critical Role in Regulation of Immune Checkpoint Proteins (ICPs) During Trophoblast Differentiation.
    Hong K; Muralimanoharan S; Kwak YT; Mendelson CR
    Endocrinology; 2022 Jul; 163(7):. PubMed ID: 35596653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of
    Fabrizio FP; Sparaneo A; Gorgoglione G; Battista P; Centra F; Delli Muti F; Trombetta D; Centonza A; Graziano P; Rossi A; Fazio VM; Muscarella LA
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism and functional verification of genes by virulence factors of P. gingivalis in ferroptosis.
    Li X; Chen T; Fu Y; Yang B; Lin X; Hou J; Yang X
    Arch Oral Biol; 2024 Jul; 163():105965. PubMed ID: 38593562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing peroxisome proliferator-activated receptor γ agonists to induce Heme Oxygenase-1: a promising approach for pulmonary inflammatory disorders.
    Lee IT; Yang CC; Yang CM
    Cell Commun Signal; 2024 Feb; 22(1):125. PubMed ID: 38360670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?
    Shelton P; Jaiswal AK
    FASEB J; 2013 Feb; 27(2):414-23. PubMed ID: 23109674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glutamine antagonists may KEAP lung cancer in check.
    Blatt EB; DeBerardinis RJ
    Sci Adv; 2024 Mar; 10(13):eado7808. PubMed ID: 38536918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
    Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
    Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
    Yu W; Chen Y; Putluri N; Osman A; Coarfa C; Putluri V; Kamal AHM; Asmussen JK; Katsonis P; Myers JN; Lai SY; Lu W; Stephan CC; Powell RT; Johnson FM; Skinner HD; Kazi J; Ahmed KM; Hu L; Threet A; Meyer MD; Bankson JA; Wang T; Davis J; Parker KR; Harris MA; Baek ML; Echeverria GV; Qi X; Wang J; Frederick AI; Walsh AJ; Lichtarge O; Frederick MJ; Sandulache VC
    Br J Cancer; 2023 Jun; 128(11):2013-2024. PubMed ID: 37012319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential regulation of proteasome functionality in reproductive vs. somatic tissues of Drosophila during aging or oxidative stress.
    Tsakiri EN; Sykiotis GP; Papassideri IS; Gorgoulis VG; Bohmann D; Trougakos IP
    FASEB J; 2013 Jun; 27(6):2407-20. PubMed ID: 23457214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.